The Oral GLP-1 Race: Orforglipron, Rybelsus, and the End of the Needle?
Eli Lilly's orforglipron, Novo's next-gen oral semaglutide, and Pfizer's danuglipron exit represent the most consequential pipeline shift in metabolic medicine. Here is the evidence as it stands in 2026.